Shilpa Medicare Limited — PPTs, 05-08-2026: Investor Presentation

Shilpa Medicare started FY27 strong: Revenue surged 43% YoY to ₹469 Cr, EBITDA grew 42% to ₹139 Cr (30% margin), and PAT jumped 115% to ₹101 Cr. Formulations revenue doubled, driven by strong US and European market growth, alongside the India launch of the novel drug NorUDCA. The API segment also rose 15%.

Strategy focuses on an integrated R&D and manufacturing approach, expanding its high-value biosimilars portfolio, complex generics, and CDMO services. Key drivers include NorUDCA for NAFLD, advancing biosimilars (like Nivolumab and Aflibercept), and Recombinant Human Albumin.

Recent highlights: The company's credit rating was upgraded to AA-. India's first integrated Antibody-Drug Conjugate (ADC) manufacturing facility was commissioned. Strategic partnerships, such as with Gate2Brain for a brain cancer therapy, are boosting novel asset development. Additionally, the Rotigotine patch secured EU marketing approval.

Financially, Adjusted ROCE reached 18.3%, and Net Debt to EBITDA improved to 1.3x, reflecting prudent financial management. Management expresses confidence in delivering a stronger FY27, anticipating improved operating leverage and margin expansion from underutilized high-margin assets across biosimilars, CDMO, and Novel Drug Delivery Systems.